FDA Blocking a New COVID-19 Treatment Because Clinical Trials Weren't American
A recent article in the New York Times details problems one pharma company is having getting approval for a new post-infection COVID-19 treatment. This post is your TL;DR for that article. Existing monoclonal antibody treatments have lost effectiveness due to new variants, and the only option for universal treatment at this point is Paxlovid. However, Paxlovid has worrisome interactions with other drugs, meaning some people can't take it. A company called Eiger Biopharmaceuticals developed and requested emergency use authorization from the FDA for a drug called pegylated interferon lambda. Interferons are proteins that signal to your immune system that there is an invader that needs to be eliminated. Interferon drugs are tricky because they signal your immune system to attack, and most kinds have receptors throughout the body. However, the company found a type of interferon whose receptors are specific to the respiratory tract. This means the drug could be usefu...